Pieris AG is an independent, clinical stage biotechnology company advancing its proprietary Anticalin® technology to create safer, more efficacious and more convenient protein therapeutics. Exclusive to Pieris, Anticalins are therapeutic proteins derived from human lipocalins, rationally engineered to solve for the pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms.
Pieris' pipeline ranges from its lead compound (anti-VEGF, oncology), which successfully completed a Phase I clinical trial in the third quarter of 2011, to multiple Anticalins in advanced preclinical development.
Pieris will clinically validate Anticalin therapeutics on its own and through strategic partnerships, involving both its proprietary pipeline and its de novo drug discovery capabilities. The company has closed several discovery and development collaborations across a very wide range of diseases, involving Daiichi Sankyo, Takeda San Francisco, the Sanofi Group and Allergan.
Privately held, Pieris has been funded by premier biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures, as well as Forbion Capital, Gilde Healthcare Partners, Novo Nordisk Ventures, BayTech Venture Capital, Bio-M, TCB, KfW and BayernKapital.